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Protein kinases: Six degrees of separation?
Michael P. Scheid and James R. Woodgett
Recent evidence for cross-talk between protein kinase B
(PKB) and the Raf-1 and NF-κB signalling pathways
has provided new hints to the complex roles that PKB
may play in regulating gene transcription and also
raised questions about where and when these targets
are relevant. 
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Recent years have witnessed an explosion of information
describing the roles of protein kinase B (PKB), also known
as c-Akt, in signal transduction. This has come about
following the revelation that PKB is regulated by the impor-
tant receptor-proximal lipid kinase phosphoinositide 3-
kinase (PI 3-kinase), and the lipid phosphatases PTEN and
SHIP. PKB may carry a significant burden of the roles that
PI 3-kinase plays in cell growth, differentiation, shape, and
survival. In recent months evidence has been published
indicating that two separate and important pathways, one
involving the transcription factor NF-κB and the other the
Ras–Raf–MAP kinase pathway, are modulated by PKB.
This cross-talk between PI 3-kinase-PKB and two seem-
ingly parallel pathways opens up many new possibilities for
how receptor activation may control cellular function. It
should also be noted that the sometimes contradictory find-
ings among these studies suggests that we should also move
with caution in defining direct targets of PKB.
The guanine-nucleotide-binding protein Ras has long
been recognised as an important proto-oncogene product,
and its proliferative signal is believed to be transmitted in
part via the serine/threonine kinase Raf-1. Raf-1 controls
the activation of the MAP kinase/Erk kinase (MEK) and
its downstream target Erk. This linear MAP kinase
pathway facilitates the communication of membrane
receptors with transcription factor targets of Erk, thereby
altering the protein activity state of any given cell during
its growth or differentiation process. It has also become
clear that the strength and duration of Erk activation are
important determinants that govern the biological
response to a particular input. 
One means by which two pathways co-activated by the
same or different receptors may subtly control divergent
targets is through cross-talk. Following this theme, a
negative role for PKB in Raf-1–Erk signalling has recently
been reported by several groups. Raf-1 activation is
complex, and involves multiple levels of membrane
recruitment, phosphorylation and binding with 14-3-3
molecules. Zimmermann et al. [1] and Rommel et al. [2]
have now shown that at least some modes of regulation of
Raf-1 involve an input from PKB, although they have
suggested somewhat different mechanisms. 
In the study reported by Zimmermann et al. [1], PKB was
shown to directly phosphorylate Raf-1 on residue
serine 259, an inactivating site, leading to reduced activity.
The site surrounding serine 259 falls into the much-hyped
‘RXRXXS’ motif, which is found in other putative PKB
targets. This motif is also a classical 14-3-3 binding region,
and binding of 14-3-3 proteins to this domain is associated
with reduced MEK phosphorylation. Zimmermann et al. [1]
further provided evidence that PKB can bind Raf-1 in
several cell types.
This model would predict a series of temporal events
following receptor activation. First, tyrosine phosphoryla-
tion at the plasma membrane would lead to activation of
both PI 3-kinase activation and Ras (the latter via recruit-
ment of the adaptor protein Grb2 and the Ras guanine-
nucleotide exchange factor Sos). Both Raf-1 and PKB
translocate from the cytoplasm to the plasma membrane
and become targets of other upstream activating kinases,
including phosphoinositide-dependent kinase 1 (PDK1)
and protein kinase C (PKC) isoforms. Raf-1 activity would
then be expected to decline, in part because of phosphoryl-
ation of serine 259 by PKB and consequent association
with 14-3-3 proteins. During tonic low levels of stimula-
tion, PKB might then place a ceiling on the overall level of
Raf-1 activity, a restriction abolished by PI 3-kinase (and
hence PKB) inhibitors. Most of the experiments reported
by Zimmermann et al. [1] involved measurements of Raf-1
activity following a single time point of stimulation, and it
will be of interest to explore the effects of PKB on Raf-1
over time. Erk often undergoes biphasic activation, and it
is tempting to speculate that this behaviour is a conse-
quence of a transient PKB ‘throttle’. 
In the work of Rommel et al. [2], the contributions of the
PKB and Raf-1 pathways were assessed during myotube
differentiation. In this system, PKB was shown to reduce
Raf-1 phosphorylation on serine 338, an activating site, in
post-differentiation myotubes. Either enforced activation
of PKB or treatment with a MEK inhibitor promoted
myotube formation, while enforced Raf-1 activity blocked
differentiation in the precursor myoblast stage. The picture
that emerges is that a balance in signal strength between
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PKB and Raf-1 decides for or against differentiation. Of
note, the effects of PKB on Raf-1 were found to be differ-
entiation-state-specific. Accordingly, an association of Raf-1
with PKB was observed only in post-differentiation
myotubes. This implies that accessory molecules, such as
14-3-3, or subcellular localization are important for
PKB–Raf-1 interaction. Downregulation of serine 338
phosphorylation would suggest activation of, or exposure
to, a phosphatase, which may be part of the PKB–Raf-1
complex. Rommel et al. [2] did not examine phosphoryla-
tion of residue serine 259. The two sets of results might be
reconciled if inhibition of Raf-1 activity through serine 259
phosphorylation leads to decreased serine 338 phosphoryla-
tion. Thus, the overall effects of PKB on Raf-1 may involve
multiple steps of phosphorylation and dephosphorylation.
These studies have uncovered an unexpected degree of
interaction between two parallel, receptor-proximal
pathways. The capacity of PKB to dampen the extent and
duration of Erk activation could provide an important
element of control for gene transcription and help explain
how two simultaneously activated, parallel pathways inter-
act to promote a cell through a differentiation or prolifera-
tion process. However, several caveats should be born in
mind when assessing the directness of the effects. First,
the use of transiently expressed, constitutively-active or
dominant-negative PKB constructs may force interactions
that rarely occur naturally. Further, some of the effects of
constitutively-active PKB on Raf-1 could be explained
through secondary activation of other kinases or phos-
phatases. Thus, while the interactions between PKB and
Raf-1 look promising, whether Raf-1 really is a direct
target of PKB remains to be firmly established.
Zimmermann et al. [1] used transformed cell lines in their
work, and it is possible that a constant level of PKB-medi-
ated Raf-1 inhibition is required for sustained proliferation
of such cells. This may explain why PKB was found to be
constitutively associated with Raf-1 in this model system,
but not in the differentiating myoblasts studied by
Rommel et al. [2]. Another complexity is the seemingly
contradictory findings by others over the past few years
that inhibition of PI 3-kinase by pharmacological inhibitors
or by expression of dominant-negative forms of PI 3-kinase
can actually reduce Erk activity [3,4]. Thus, PI 3-kinase
may play several distinct roles in the regulation of the Erk
pathway, both positive and negative, depending on the
input signal and strength, the cell type and the differentia-
tion state (Figure 1). The two new studies [1,2] highlight
the differences that can occur between cell-type systems
and further dispel the myth that signal transduction path-
ways are generic or ‘hardwired’.
In the course of investigating a completely different
signalling arm, three laboratories [5–7] have uncovered a
link between NF-κB activation and the PI 3-kinase–PKB
pathway (Figure 2). Unlike the antagonism mediated by
PKB on Raf-1 activation, PKB was found to increase NF-κB
activation. Weiss and colleagues [5] first demonstrated in
T-cell lines that activated PKB synergistically elevated
NF-κB-mediated gene expression following stimulation
with phorbol esters [5]. Further mechanistic details were
later provided by two other groups [6,7], who showed that
agonists that induce NF-κB activation, such as tumour
necrosis factor α (TNF-α) or platelet-derived growth factor
(PDGF), can act in part through PKB activation to activate
IKK, the upstream kinase that phosphorylates the inhibitory
component I-κB. Phosphorylation of I-κB by IKK leads to
its ubiquitinylation and degradation, freeing the cytosolic
NF-κB to translocate to the nucleus where it can modulate
gene expression. But the new studies show that this model
of activation is complex, and, as in the case of Raf modula-
tion described above, there are some conspicuous differ-
ences between the inferred mechanism in each study that
may be attributable to cell type or experimental approach.
In one study [6], inhibitors of PI 3-kinase or a dominant-
negative form of PKB were found to ablate TNF-α-induced
R192 Current Biology Vol 10 No 5
Figure 1
Depending on the cellular context, Raf-1 and
PKB may induce opposing cell responses,
such as differentiation versus proliferation, or
apoptosis versus survival. The balance
between these decisions is controlled by the
strength and duration of Raf-1 and PKB
activation. Many of the positive inputs into
Raf-1 are shared with PKB, resulting in
simultaneous activation. PKB may tip the
scale in its favour when it is turned on by
directly suppressing Raf-1.
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activation of NF-κB in 293 cells. Furthermore, a constitu-
tively-active form of PKB stimulated NF-κB to a similar
degree as TNF-α, showing that active PKB alone is suffi-
cient to drive NF-κB activation in these cells. In contrast,
in experiments with human fibroblasts [7], inhibition of PI
3-kinase had no effect on TNF-α-induced NF-κB activa-
tion, indicating that PKB is dispensable for NF-κB activa-
tion in these cells. Observations supporting this view were
recently made in dendritic cells and osteoclasts, where the
TNF-α-related protein TRANCE was shown to activate
both PKB and NF-κB through independent pathways [8].
Another significant difference between these studies
involved the association of PKB with its suspected target,
IKK. While the association appears to be constitutive in
293 cells, it was transient in primary fibroblasts. And if this
scenario was not already complex enough, a separate study
has suggested that PKB directly phosphorylates and regu-
lates NF-κB, independent of effects on I-κB stability [9].
Together, these findings indicate that PKB contributes
multiple inputs leading to NF-κB activation, some of
which are dependent on the cellular system.
Of the many cellular processes governed by PI 3-kinase,
one major outcome of PKB activation is protection from
apoptosis [10]. With the expanding list of substrates
assigned to PKB, the opportunities that present themselves
for survival signalling are also growing, and include human
caspase-9, Bad and Forkhead transcription factors [11].
Raf-1 and NF-κB can now be included in this list. Expres-
sion of an oncogenic form of Ras can induce apoptosis, sug-
gesting that inappropriate activation of the Raf–MAP
kinase pathway, particularly in the absence of PI
3-kinase/PKB signalling, triggers an apoptotic signal. Thus,
PKB may provide some protection from apoptosis by sup-
pressing excessive Raf-1 signalling (too much of a good
thing...). The pro-survival effects of activated NF-κB are
well documented [12], and so the relevance of an input
from PKB is obvious.
Other pathways besides NF-κB and Raf-1 are likely to
contribute to the pro-survival function of PKB. Members
of the Forkhead family of transcription factors are among
the most plausible targets — in this case, the evidence
from experiments with mammalian cell lines is supported
by earlier genetic experiments performed in Caenorhabditis
elegans [13,14]. But the relevance of some of the other sug-
gested targets has been questioned — in the case of
caspase-9, for example, the ‘RXRXXS’ motif phosphory-
lated by PKB in the human enzyme is absent in the
mouse homolog [15]. 
The relationship between PKB and Bad is similarly com-
plicated. Early evidence correlated Bad phosphorylation,
which reduces its pro-apoptotic activity, with expression
of activated PKB or decreased Bad phosphorylation fol-
lowing treatment with PI 3-kinase inhibitors. Further-
more, the Bad phosphorylation level was found to be
elevated in cell lines deficient for PTEN lipid phos-
phatase activity  [16]. PTEN is a negative regulator of
PKB, and so the effects observed were attributed to the
elevated PKB activity in these cells. But, as in the case of
Raf-1, it would appear that PKB activation does not always
lead to Bad phosphorylation [17]. 
There is emerging evidence that the Ras–MAP kinase
pathway may also play a significant role in increasing Bad
phosphorylation [17,18]. As discussed above, given that
there may be cross-talk between the PI 3-kinase–PKB
pathway and the Ras-MAP kinase pathway at various
levels, with both positive and negative interactions, some
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Figure 2
Until recent years, three separate pathways
were believed to operate downstream of
growth factor receptors to regulate gene
transcription, survival and differentiation (left
panel). Now these pathways can be unified,
providing interdependence and coordination
of signalling consequences (right panel).
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of the effects on Bad attributed to PI 3-kinase and PKB
may in fact be due to changes in MAP kinase activity
(Figure 2). This view is supported by the observation that
expression of PTEN decreases Bad phosphorylation at
sites targeted in vivo by the Ras–MAP kinase pathway as
well as PKB [16,19].
These examples highlight the difficulties associated with
studying intertwined pathways initially thought to operate
independently, and, in particular, with identifying direct
substrates of PKB (or any protein kinase for that matter).
A common factor in all of these studies is the use of tran-
siently expressed, constitutively-active PKB. This genetic
tool has been useful in sorting out the various inputs that
PKB makes in the global cellular network, while avoiding
the lack of specificity associated with pharmacological
inhibitors of PI 3-kinase. But it also has its pitfalls: a lack
of similarity to the time-course of PKB activation that nat-
urally follows receptor activation; a disproportionate level
of PKB protein compared to endogenous binding partners
and substrates; and the possibility of complication by
autocrine or paracrine signalling events, especially as PKB
affects gene expression by a host of potential targets, such
as the Forkhead and NF-κB transcription factors. Studies
that use rapid, inducible activation strategies and selective
small-molecule inhibitors of PKB will be crucial in more
closely approximating the temporal activation of PKB that
naturally follows cell stimulation by a growth factor, and
should help in assessing which PKB targets are truly phys-
iologically relevant and under what circumstances.
Acknowledgements
M.P.S. is supported by an Amgen fellowship. J.R.W. is supported by grants
from the MRC (Canada), NCIC and HHMI.
References
1. Zimmermann S, Moelling K: Phosphorylation and regulation of Raf
by Akt (protein kinase B). Science 1999, 286:1741-1744.
2. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K,
Moelling K, Yancopoulos GD, Glass DJ: Differentiation stage-specific
inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999,
286:1738-1741.
3. Sutor SL, Vroman BT, Armstrong EA, Abraham RT, Karnitz LM: A
phosphatidylinositol 3-kinase-dependent pathway that differentially
regulates c-Raf and A-Raf. J Biol Chem 1999, 274:7002-7010.
4. Wennstrom S, Downward J: Role of phosphoinositide 3-kinase in
activation of ras and mitogen-activated protein kinase by
epidermal growth factor. Mol Cell Biol 1999, 19:4279-4288.
5. Kane LP, Shapiro VS, Stokoe D, Weiss A: Induction of NF-kappaB
by the Akt/PKB kinase. Curr Biol 1999, 9:601-604.
6. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB:
NF-kappaB activation by tumour necrosis factor requires the Akt
serine-threonine kinase. Nature 1999, 401:82-85.
7. Romashkova JA, Makarov SS: NF-kappaB is a target of AKT in
anti-apoptotic PDGF signalling. Nature 1999, 401:86-90.
8. Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H,
Choi Y: TRANCE, a TNF family member, activates Akt/PKB
through a signalling complex involving TRAF6 and c-Src. Mol Cell
1999, 4:1041-1049.
9. Sizemore N, Leung S, Stark GR: Activation of phosphatidylinositol
3-kinase in response to interleukin-1 leads to phosphorylation
and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol
1999, 19:4798-4805.
10. Stambolic V, Mak TW, Woodgett JR: Modulation of cellular
apoptotic potential: contributions to oncogenesis. Oncogene
1999, 18:6094-6103.
11. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three
Akts. Genes Dev 1999, 13:2905-2927.
12. Pahl HL: Activators and target genes of Rel/NF-kappaB
transcription factors. Oncogene 1999, 18:6853-6866.
13. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ,
Arden KC, Blenis J, Greenberg ME: Akt promotes cell survival by
phosphorylating and inhibiting a Forkhead transcription factor.
Cell 1999, 96:857-868.
14. Paradis S, Ruvkun G: Caenorhabditis elegans Akt/PKB transduces
insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16
transcription factor. Genes Dev 1998, 12:2488-2498.
15. Fujita E, Jinbo A, Matuzaki H, Konishi H, Kikkawa U, Momoi T: Akt
phosphorylation site found in human caspase-9 is absent in mouse
caspase-9. Biochem Biophys Res Commun 1999, 264:550-555.
16. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA,
Wigler MH, Downes CP, Tonks NK: The lipid phosphatase activity
of PTEN is critical for its tumor supressor function. Proc Natl Acad
Sci USA 1998, 95:13513-13518.
17. Scheid MP, Schubert KM, Duronio V: Regulation of Bad
phosphorylation and association with Bcl-x(L) by the MAPK/Erk
kinase. J Biol Chem 1999, 274:31108-31113.
18. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME:
Cell survival promoted by the Ras-MAPK signaling pathway by
transcription-dependent and -independent mechanisms. Science
1999, 286:1358-1362.
19. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA,
Khan H, Furui T, Mao M, et al.: The PTEN/MMAC1/TEP tumor
suppressor gene decreases cell growth and induces apoptosis
and anoikis in breast cancer cells. Oncogene 1999, 18:7034-7045.
R194 Current Biology Vol 10 No 5
bb10e09.qxd  03/13/2000  01:47  Page R194
